Skip to main content

Table 1 Baseline clinical and cardiac MRI characteristics categorized by presence of myocardial fibrosis

From: Prognostic value of preoperative myocardial fibrosis assessment by delayed enhancement cardiac magnetic resonance imaging in patients undergoing mitral valve repair

Variables

All patients

(N = 48)

NO fibrosis

(N = 29)

WITH fibrosis

(N = 19)

P

Age, years (SD)

61 (13)

59 (11)

65 (15)

0.112

Male sex, No. (%)

33 (69)

18 (62.1)

15 (78.9)

0.217

BMI, kg/m2 (range)

28.4 (19.0-56.1)

27.0 (19.0-56.1)

29.4 (19.5-53.5)

0.348

Functional mitral regurgitation, No. (%)

13 (27.1)

5 (17.2)

8 (42.1)

0.06

History of diabetes mellitus, No. (%)

7 (14.6)

3 (10.3)

4 (21.1)

0.31

History of dyslipidemia, No. (%)

23 (47.9)

11 (37.9)

12 (63.2)

0.09

History of hypertension, No. (%)

30 (62.5)

16 (55.2)

14 (73.7)

0.20

Hemoglobin level on admission, g/dL (range)

13 (7-16)

13.0 (8.0-15.0)

13.0 (7.0-16.0)

0.574

Statins, No. (%)

14 (29.2)

6 (20.7)

8 (42.1)

0.110

ACEI or ARB, No. (%)

19 (39.6)

8 (27.6)

11 (57.9)

0.036

β blockers, No. (%)

25 (52.1)

12 (41.4)

13 (68.4)

0.067

Aspirin, No. (%)

22 (45.8)

13 (44.8)

9 (47.4)

0.863

Cardiac MRI LVEF, % (SD)

63.04 (11.86)

63.31 (12.34)

62.63 (11.40)

0.85

Cardiac MRI RVEF, % (SD)

52.00 (10.33)

52.97 (10.62)

48.84 (9.60)

0.18

Cardiac MRI LVEDV, mL (SD)

200.00(61.34)

199.42 (57.56)

198.34 (68.33)

0.95

Cardiac MRI LVESV, mL (SD)

68.50 (41.03)

75.63 (40.25)

76.50 (43.31)

0.94